RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dortmund corrects Svenja Schlenker contract term to Dec. 31, 2028 from June 30, 2028
From Shopify to Zoom: Meta (META.US) equips Muse with a complete toolbox for small businesses
Meta has launched the Muse AI agent for small businesses, which can be integrated with more than ten tools including Shopify and Stripe. Its stock price has increased by 25% in September.
Uncertainty clouds the US stock IPO market as smart ring manufacturer Oura (OURA.US) joins the ranks of delayed listings
Oura (OURA.US) has become the latest company to postpone its initial public offering (IPO) in the United States due to market uncertainty.
Scholastic to Acquire Cottage Door Press for $71 Million
Crypto prices
More
